S&P 500   2,590.88 (-98.27%)
DOW   21,991.02 (+1.64%)
QQQ   190.07 (+2.57%)
AAPL   252.42 (+1.89%)
FB   159.43 (+1.68%)
MSFT   158.07 (+5.59%)
GOOGL   1,126.15 (+1.43%)
AMZN   1,964.52 (+3.39%)
CGC   14.40 (-1.91%)
NVDA   261.20 (+3.35%)
BABA   188.43 (-0.08%)
MU   44.72 (+2.85%)
GE   7.78 (-0.38%)
TSLA   504.00 (-2.01%)
AMD   48.22 (+3.52%)
T   29.74 (-0.34%)
ACB   0.95 (-7.79%)
F   5.03 (-3.08%)
NFLX   372.19 (+4.22%)
BAC   21.93 (+1.53%)
GILD   75.42 (+3.53%)
PRI   89.96 (-0.30%)
DIS   96.61 (+0.21%)
S&P 500   2,590.88 (-98.27%)
DOW   21,991.02 (+1.64%)
QQQ   190.07 (+2.57%)
AAPL   252.42 (+1.89%)
FB   159.43 (+1.68%)
MSFT   158.07 (+5.59%)
GOOGL   1,126.15 (+1.43%)
AMZN   1,964.52 (+3.39%)
CGC   14.40 (-1.91%)
NVDA   261.20 (+3.35%)
BABA   188.43 (-0.08%)
MU   44.72 (+2.85%)
GE   7.78 (-0.38%)
TSLA   504.00 (-2.01%)
AMD   48.22 (+3.52%)
T   29.74 (-0.34%)
ACB   0.95 (-7.79%)
F   5.03 (-3.08%)
NFLX   372.19 (+4.22%)
BAC   21.93 (+1.53%)
GILD   75.42 (+3.53%)
PRI   89.96 (-0.30%)
DIS   96.61 (+0.21%)
S&P 500   2,590.88 (-98.27%)
DOW   21,991.02 (+1.64%)
QQQ   190.07 (+2.57%)
AAPL   252.42 (+1.89%)
FB   159.43 (+1.68%)
MSFT   158.07 (+5.59%)
GOOGL   1,126.15 (+1.43%)
AMZN   1,964.52 (+3.39%)
CGC   14.40 (-1.91%)
NVDA   261.20 (+3.35%)
BABA   188.43 (-0.08%)
MU   44.72 (+2.85%)
GE   7.78 (-0.38%)
TSLA   504.00 (-2.01%)
AMD   48.22 (+3.52%)
T   29.74 (-0.34%)
ACB   0.95 (-7.79%)
F   5.03 (-3.08%)
NFLX   372.19 (+4.22%)
BAC   21.93 (+1.53%)
GILD   75.42 (+3.53%)
PRI   89.96 (-0.30%)
DIS   96.61 (+0.21%)
S&P 500   2,590.88 (-98.27%)
DOW   21,991.02 (+1.64%)
QQQ   190.07 (+2.57%)
AAPL   252.42 (+1.89%)
FB   159.43 (+1.68%)
MSFT   158.07 (+5.59%)
GOOGL   1,126.15 (+1.43%)
AMZN   1,964.52 (+3.39%)
CGC   14.40 (-1.91%)
NVDA   261.20 (+3.35%)
BABA   188.43 (-0.08%)
MU   44.72 (+2.85%)
GE   7.78 (-0.38%)
TSLA   504.00 (-2.01%)
AMD   48.22 (+3.52%)
T   29.74 (-0.34%)
ACB   0.95 (-7.79%)
F   5.03 (-3.08%)
NFLX   372.19 (+4.22%)
BAC   21.93 (+1.53%)
GILD   75.42 (+3.53%)
PRI   89.96 (-0.30%)
DIS   96.61 (+0.21%)
Log in

NASDAQ:NVIV - Invivo Therapeutics Stock Price, Forecast & News

$1.42
-0.02 (-1.40 %)
(As of 03/30/2020 10:53 AM ET)
Today's Range
$1.43
Now: $1.43
$1.48
50-Day Range
$0.20
MA: $3.66
$8.10
52-Week Range
$1.09
Now: $1.43
$50.70
Volume794 shs
Average Volume277,068 shs
Market Capitalization$840,750.00
P/E RatioN/A
Dividend YieldN/A
Beta1.19
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Read More
Invivo Therapeutics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.15 per share

Profitability

Net Income$-11,830,000.00

Miscellaneous

Employees6
Market Cap$840,750.00
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.


Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

How has Invivo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Invivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVIV shares have decreased by 10.9% and is now trading at $1.4250. View which stocks have been mosted impacted by Coronavirus.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 6th 2020. View our earnings forecast for Invivo Therapeutics.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($224.40) EPS for the quarter, missing the consensus estimate of ($12.30) by $212.10. View Invivo Therapeutics' earnings history.

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics shares reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Has Invivo Therapeutics been receiving favorable news coverage?

Press coverage about NVIV stock has been trending somewhat negative on Monday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Invivo Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutInvivo Therapeutics.

Are investors shorting Invivo Therapeutics?

Invivo Therapeutics saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 22,600 shares, a decline of 42.5% from the February 27th total of 39,300 shares. Based on an average daily volume of 443,500 shares, the short-interest ratio is presently 0.1 days. Currently, 3.9% of the shares of the company are short sold. View Invivo Therapeutics' Current Options Chain.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the following people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are Invivo Therapeutics' major shareholders?

Invivo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (6.81%) and Renaissance Technologies LLC (4.46%). View institutional ownership trends for Invivo Therapeutics.

Which institutional investors are buying Invivo Therapeutics stock?

NVIV stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., and Renaissance Technologies LLC. View insider buying and selling activity for Invivo Therapeutics.

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.43.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $840,750.00. The biotechnology company earns $-11,830,000.00 in net income (profit) each year or ($67.57) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe. View additional information about Invivo Therapeutics.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com/.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  227 (Thanks for Voting!)
Underperform Votes:  184 (Thanks for Voting!)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel